Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study
Identificadores
Identificadores
Data de publicación
2012Título da revista
ONCOLOGIST
Tipo de contido
Artigo